Bexxar (iodine I 131 tositumomab)
Published: Oct 15, 2008 8:00 am
| Brand Name: | Bexxar |
| Generic Name: | iodine I 131 tositumomab |
| Code Name: | |
| Company: | GlaxoSmithKline |
| FDA Clinical Phase: | 2 |
Description:
Bexxar is a monoclonal antibody to which radioactive iodine 131 is attached, which targets a protein called CD20 found on the surface of a variety of B-cells, including lymphoma cells, and some myeloma cells. The radioactive iodine attached to the antibody delivers radiation directly to these cells which works to harm or kill the cancer cells. Approximately 20-25% of patients with multiple myeloma have this protein on the surface of their tumor cells.
Clinical Trials:
For a list of clinical trials studying Bexxar for the treatment of multiple myeloma, see ClinicalTrials.gov.
Official website for Bexxar: http://www.bexxar.com/
Source: ClinicalTrials.gov, Multiple Myeloma AND Bexxar, http://www.clinicaltrial.gov/ct2/show/NCT00135200?term=multiple+myeloma+AND+bexxar&rank=1 (as of August 27, 2008)
Related Articles:
- IMW 2009 – Elotuzumab And Panobinostat Clinical Trials With Velcade
- New Myeloma Drugs Target Different Mechanisms Of Action: Cell Surface Receptors
- Beacon NewsFlashes – July 4, 2011
- Istodax Achieves Little Response In Refractory Multiple Myeloma
- New Advances In Myeloma Vaccines – Part 2: Types Of Potential Myeloma Therapeutic Vaccines
Leave a comment